FDA approves Welireg with pembrolizumab for renal cell carcinoma

The U.S.

Food and Drug Administration has approved Merck's Welireg (belzutifan) in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for the adjuvant treatment of renal cell carcinoma in adults with a clear cell component at intermediate-high or high risk for recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ...